On August 5, 2015, Exosome Diagnostics, Inc., a developer of what it terms “revolutionary, biofluid-based molecular diagnostics,” announced data demonstrating the ability of its proprietary exosomal RNA (exoRNA) plus cell-free DNA (cfDNA) platform to detect, with high sensitivity, EGFR-activating mutations and the EGFR T790M resistance mutation in the blood plasma of patients with non-small cell lung cancer (NSCLC). The data were first presented on July 31, 2015 at a poster session (http://www.exosomedx.com/sites/default/files/uploads/publications/ilcc_exosomediagnostics_egfr_t790m.pdf) titled, “Detection of EGFR-Activating and T790M Resistance Mutation in Plasma of NSCLC Patients Using Combined Exosomal RNA and cfDNA capture,” presented during the 16th Annual International Lung Cancer Congress (http://www.gotoper.com/conferences/ilc/meetings/16th-international-lung-cancer-congress), which took place July 30 – August 1, 2015 in Huntington Beach, California. “Unfortunately, non-small cell lung cancer is very smart; it develops new mutations over time to resist treatment, including the EGFR T790M mutation,” said Vince O’Neill, M.D., Chief Medical Officer at Exosome Diagnostics. “Based on these new data we presented, we’re highly encouraged that our EGFR T790M test will give medical oncologists a critical new tool to non-invasively, and with high sensitivity, detect the development of this resistance mutation over time through a simple blood draw, helping inform the most appropriate, targeted, and timely treatment decisions for patients, as their disease progresses.” In the study, Exosome Diagnostics applied its exoRNA plus cfDNA platform to isolate exoRNA and cfDNA from 21 blood plasma samples from NSCLC patients collected at the time of clinical resistance to EGFR tyrosine kinase inhibitor (TKI) therapy.
Login Or Register To Read Full Story